biomarkers for prostate cancer program
Miraculins spots biomarkers for prostate cancer program
2006-09-06 09:36 ET - News Release
Dr. Jim Charlton reports
MIRACULINS ANNOUNCES RESULTS OF VALIDATION STUDY
Miraculins Inc. has successfully completed the validation study for its prostate cancer diagnostic program.
In a study of 180 patients, Miraculins was able to validate three biomarkers that were highlighted in the previous discovery phase study. The patients were recruited in collaboration with the Winnipeg Clinic and the Alberta Urology Institute and were independent from the patients samples collected for the company's discovery study.
"We are very pleased to announce these positive results. The successful validation of three biomarkers will allow the Miraculins test to be marketed as a panel diagnostic. It is widely recognized that panel diagnostics have the ability to provide greater accuracy than single-marker diagnostics," stated Dr. Jim Charlton, president of Miraculins. "The study also provided evidence that with simple adjustments the precision of the test could be even further improved."
Additional research has already begun on the diagnostic and an additional set of patient samples is currently being collected and studied using a secondary protocol. Purification and identification of all of the biomarkers is presently continuing after which Miraculins will be in a position to present the overall classification results of the study.
"Of particular excitement is that the diagnostic's primary protein biomarker achieved results equalling its performance in the discovery study," added Dr. Charlton. "The success of the validation study means continued investment in the test including adapting the test into an immunoassay format, applying for regulatory approvals, and developing further commercialization and marketing refinements."
We seek Safe Harbor.